Key Factors to Evaluate Before Investing in Bausch + Lomb (BLCO)

By Blake Campbell • Monday, September 16 15:10 • Permanent Link

With gains of 15.8%, Bausch + Lomb was one of the winners on Wall Street today. Its shares are now trading at $18.0 and have logged a 0.0% daily outperformance of the S&P 500. Don't join the feeding frenzy before checking some basic facts about this stock:

Bausch + Lomb has moved -11.8% over the last year, and the S&P 500 logged a change of 26.3%
BLCO has an average analyst rating of buy and is -33.8% away from its mean target price of $27.19 per share
Its trailing earnings per share (EPS) is $-1.29
Bausch + Lomb has a trailing 12 month Price to Earnings (P/E) ratio of -14.0 while the S&P 500 average is 28.21
Its forward earnings per share (EPS) is $1.16 and its forward P/E ratio is 15.5
The company has a Price to Book (P/B) ratio of 0.97 in contrast to the S&P 500's average ratio of 4.71
Bausch + Lomb is part of the Health Care sector, which has an average P/E ratio of 27.61 and an average P/B of 3.69
The company has a free cash flow of $-88875000, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.